Ligand Pharmaceuticals | LGND - مصروفات التشغيل





مصروفات التشغيل تغيير تاريخ
Agenus USD 19.81M 293.94M 2025-12
Amgen USD 4.78B 1.12B 2026-03
Anika Therapeutics USD 133.9M 103.93M 2026-03
Arrowhead Research USD 223.22M 10.86M 2025-12
Baxter International USD 6.04B 2.85B 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Enviri Corporation USD 590.29M 229.2M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 513.55M 109.86M 2025-12
Intrexon USD 61.56M 26.1M 2024-06
Ionis Pharmaceuticals USD 364M 54M 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Ligand Pharmaceuticals USD 8.29M 32.17M 2025-09
MacroGenics USD 53.32M 13.68M 2025-12
Merck USD 18.17B 8.01B 2026-03
Pacira USD 172.75M 20.93M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Veracyte USD 116M 7.24M 2025-12